Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 10/2017

01-10-2017 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases

Authors: Joyce M. Richey, Orison Woolcott

Published in: Current Diabetes Reports | Issue 10/2017

Login to get access

Abstract

Purpose of review

The purpose of the review was to revisit the possibility of the endocannabinoid system being a therapeutic target for the treatment of obesity by focusing on the peripheral roles in regulating appetite and energy metabolism.

Recent findings

Previous studies with the global cannabinoid receptor blocker rimonabant, which has both central and peripheral properties, showed that this drug has beneficial effects on cardiometabolic function but severe adverse psychiatric side effects. Consequently, focus has shifted to peripherally restricted cannabinoid 1 (CB1) receptor blockers as possible therapeutic agents that mitigate or eliminate the untoward effects in the central nervous system.

Summary

Targeting the endocannabinoid system using novel peripheral CB1 receptor blockers with negligible penetrance across the blood-brain barrier may prove to be effective therapy for obesity and its co-morbidities. Perhaps the future of blockers targeting CB1 receptors will be tissue-specific neutral antagonists (e.g., skeletal muscle specific to treat peripheral insulin resistance, adipocyte-specific to treat fat excess, liver-specific to treat fatty liver and hepatic insulin resistance).
Literature
1.
• Sellayah D, Cagampang FR, Cox RD. On the evolutionary origins of obesity: a new hypothesis. Endocrinology. 2014;155(5):1573–88. This study underscores the need to combat obesity CrossRefPubMed
2.
Apovian CM. The clinical and economic consequences of obesity. Am J Manag Care. 2013;19(11):S219–S28.
3.
Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med. 2007;120(9 Suppl 1):S10–6. discussion S6-7CrossRefPubMed
4.
Haffner SM. Type 2 diabetes and the metabolic syndrome: National Cholesterol Education Program guidelines and supporting evidence. Crit Pathw Cardiol. 2004;3(3 Suppl):S12-4.CrossRefPubMed
5.
Cervino C, Pasquali R, Pagotto U. Cannabinoid receptor antagonists and the metabolic syndrome: novel promising therapeutical approaches. Mini-Rev Med Chem. 2007;7(1):21–30.CrossRefPubMed
6.
Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 2006;6(6):586–91.CrossRefPubMed
7.
Despres JP, Lemieux I, Almeras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes. 2006;30:S44–52.CrossRef
8.
Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal-transduction. Proc Natl Acad Sci U S A. 1993;90(16):7656–60.CrossRefPubMedPubMedCentral
9.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.CrossRefPubMed
10.
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588–631.CrossRefPubMedPubMedCentral
11.
Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology. 2014;76 Pt B:228–34.CrossRefPubMed
12.
13.
Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585–9.CrossRefPubMed
14.
Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord. 2003;27(3):289–301.CrossRefPubMed
15.
Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423–31.CrossRefPubMedPubMedCentral
16.
Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci. 2009;30(1):1–7.CrossRefPubMed
17.
Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120(8):2953–66.CrossRefPubMedPubMedCentral
18.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838–43.CrossRefPubMedPubMedCentral
19.
Mechoulam R, Devane WA, Glaser R. Cannabinoid geometry and biological activity. In: Nahas G, Sutin KM, Harvey D, Agurell S, Pace N, Camcro R, editors. Marihuana and Medicine. Ottawa: Humana Press; 1999. p. 65-90.
20.
21.
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother. 1993;27(7–8):827–31.CrossRefPubMed
22.
Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008;29(5):229–33.CrossRefPubMed
23.
Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Investig. 2006;29(3 Suppl):15–26.
24.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, Group R-ES. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–97.CrossRefPubMed
25.
Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31(Suppl 2):S229–40.CrossRefPubMed
26.
Despres JP, Golay A, Sjostrom L. Rimonabant Obesity Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121–34.CrossRefPubMed
27.
Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol. 2007;293(6):R2185–93.CrossRefPubMed
28.
Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring). 2011;19(7):1325–34.CrossRef
29.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, Group R-NAS. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761–75.CrossRefPubMed
30.
Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol. 2008;20(Suppl 1):139–46.CrossRefPubMed
31.
Ducobu J, Sternon J. Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system. J Pharm Belg. 2005;60(3):89–91.PubMed
32.
33.
Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes. 2007;31(4):692–9.
34.
Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2009;52(2):213–7.CrossRefPubMed
35.
Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S66–78.CrossRefPubMed
36.
Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51(8):1356–67.CrossRefPubMed
37.
Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008;16(3):553–65.CrossRef
38.
Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol. 2007;18(2):129–40.CrossRefPubMed
39.
Herling AW, Kilp S, Juretschke HP, Neumann-Haefelin C, Gerl M, Kramer W. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes. 2008;32(9):1363–72.CrossRef
40.
Richey JM, Woolcott OO, Stefanovski D, Harrison LN, Zheng D, Lottati M, et al. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. Am J Physiol Endocrinol Metab. 2009;296(6):E1311–8.CrossRefPubMedPubMedCentral
41.
Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia. 2001;44(3):312–9.CrossRefPubMed
42.
Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781(4):200–12.CrossRefPubMed
43.
Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A. 2001;98(11):6402–6.CrossRefPubMedPubMedCentral
44.
•• Argueta DA, DiPatrizio NV. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav. 2017;171:32–9. Study demonstrates enhanced endocannabinoid signaling at peripheral CB1 receptors with fat feeding CrossRefPubMed
45.
Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298–305.CrossRefPubMedPubMedCentral
46.
47.
Engeli S, Lehmann AC, Kaminski J, Haas V, Janke J, Zoerner AA, et al. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. Obesity (Silver Spring). 2014;22(5):E70–6.CrossRef
48.
Kim SP, Woolcott OO, Hsu IR, Stefanoski D, Harrison LN, Zheng D, et al. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. Am J Physiol Endocrinol Metab. 2012;302(10):E1261–8.CrossRefPubMedPubMedCentral
49.
Kabir M, Stefanovski D, Hsu IR, Iyer M, Woolcott OO, Zheng D, et al. Large size cells in the visceral adipose depot predict insulin resistance in the canine model. Obesity (Silver Spring). 2011;19(11):2121–9.CrossRef
50.
Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4):640–8.CrossRefPubMed
51.
Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19(11):1567–9.PubMed
52.
53.
•• Kabir M, Iyer MS, Richey JM, Woolcott OO, Asare Bediako I, Wu Q, et al. CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors. Am J Physiol Endocrinol Metab. 2015;309(8):E747–58. Study demonstrates the importance of adiponectin in improving insulin sensitivity with CB1 antagonism CrossRefPubMedPubMedCentral
54.
Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology. 2008;149(5):2557–66.CrossRefPubMed
55.
Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008;20(6):850–7.CrossRefPubMed
56.
Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1101–4.CrossRefPubMed
57.
Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118(9):3160–9.CrossRefPubMedPubMedCentral
58.
Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–60.CrossRefPubMedPubMedCentral
59.
Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 2005;280(26):25196–201.CrossRefPubMed
60.
Kola B, Wittman G, Bodnár I, Amin F, Lim CT, Oláh M, et al. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J. 2013;27(12):5112–21.CrossRefPubMedPubMedCentral
61.
Gamelin FX, Aucouturier J, Iannotti FA, Piscitelli F, Mazzarella E, Aveta T, et al. Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. J Physiol Biochem. 2016;72(2):183–99.CrossRefPubMed
62.
Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res. 2006;38(5):356–8.CrossRefPubMed
63.
Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008;57(11):2977–91.CrossRefPubMedPubMedCentral
64.
•• Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013;23(17):4751–60. This study provides a nice description of peripheral CB1 blockade CrossRefPubMed
65.
Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19(12):pyw068.CrossRefPubMedPubMedCentral
66.
Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016;5(12):1187–99.CrossRefPubMedPubMedCentral
67.
Chorvat RJ, Berbaum J, Seriacki K, McElroy JF. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012;22(19):6173–80.CrossRefPubMed
68.
•• Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013;76(6):846–57. Study provides evidence for minimal brain penetrance of a CB1 blocker in humans CrossRefPubMedPubMedCentral
69.
•• Takano A, Gulyas B, Varnas K, Little PB, Noerregaard PK, Jensen NO, et al. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study. Synapse. 2014;68(3):89–97. Study provides promising results for second-generation CB1 antagonism as an anti-obesity drug CrossRefPubMed
70.
Hung M-S, Chang C-P, Li T-C, Yeh T-K, Song J-S, Lin Y, et al. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. Chem Med Chem. 2010;5(9):1439–43.CrossRefPubMed
71.
Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol Res. 2013;74:94–108.CrossRefPubMed
72.
Lazzari P, Serra V, Marcello S, Pira M, Mastinu A. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Eur Neuropsychopharmacol. 2017;27(7):667–78.CrossRefPubMed
73.
Rossi F, Bellini G, Luongo L, Manzo I, Tolone S, Tortora C, et al. Cannabinoid receptor 2 as antiobesity target: inflammation, fat storage, and Browning modulation. J Clin Endocrinol Metab. 2016;101(9):3469–78.CrossRefPubMed
74.
Verty AN, Stefanidis A, McAinch AJ, Hryciw DH, Oldfield B. Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One. 2015;10(11):e0140592.CrossRefPubMedPubMedCentral
75.
LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009;19(3):639–43.CrossRefPubMed
76.
Matthews JM, McNally JJ, Connolly PJ, Xia M, Zhu B, Black S, et al. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists. Bioorg Med Chem Lett. 2016;26(21):5346–9.CrossRefPubMed
77.
Gonzalez-Mariscal I, Krzysik-Walker SM, Doyle ME, Liu QR, Cimbro R, Santa-Cruz Calvo S, et al. Human CB1 receptor isoforms, present in hepatocytes and beta-cells, are involved in regulating metabolism. Sci Rep. 2016;6:33302.CrossRefPubMedPubMedCentral
78.
Dow RL, Carpino PA, Gautreau D, Hadcock JR, Iredale PA, Kelly-Sullivan D, et al. Design of a potent CB1 receptor antagonist series: potential scaffold for peripherally-targeted agents. ACS Med Chem Lett. 2012;3(5):397–401.CrossRefPubMedPubMedCentral
Metadata
Title
Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases
Authors
Joyce M. Richey
Orison Woolcott
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2017
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-017-0924-x

Other articles of this Issue 10/2017

Current Diabetes Reports 10/2017 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Obesity (J McCaffery, Section Editor)

The Immune System in Obesity: Developing Paradigms Amidst Inconvenient Truths

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Animal Models of Diabetic Retinopathy

Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Management of Type 1 Diabetes in the Hospital Setting

Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits